Dilur

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dilur

Quick Facts

Property Description
Active ingredient Doxazosin (as the mesylate salt)
Form Tablet (Oral formulation)
Pharmacological class Alpha-1 Adrenergic Receptor Antagonist (alpha-1-Blocker)
General Purpose Managing elevated circulatory pressure and easing smooth muscle tension
Origin Synthetic compound (Quinazoline derivative)

Dilur: A Definition and Pharmacological Classification

Dilur is a prescription-only medicine containing the active ingredient Doxazosin, typically prepared as Doxazosin mesylate. It belongs to the selective Alpha-1 adrenergic receptor antagonist pharmacological class, commonly recognized as an alpha-1-blocker. This classification means the substance targets and inhibits specific alpha-1 adrenoceptors within the body. Doxazosin is structurally identified as a quinazoline derivative, a synthetic compound manufactured for therapeutic use, a feature that distinguishes it chemically from agents belonging to different classes.

Composition, Origin, and Pharmaceutical Form of Doxazosin

The essential component of the medicine is Doxazosin mesylate, which is the sole active agent, making Dilur a single-ingredient product. The drug is designed for oral administration and is supplied as a tablet, representing its standard oral formulation. The final tablet form consists of the precise measure of Doxazosin mesylate combined with necessary inactive materials, known as excipients. Dilur is clinically recognized for its versatility in formulation, as both immediate-release and prolonged-release oral formulations exist, offering differing therapeutic profiles related to absorption rates.

General Purpose of an Alpha-1 Adrenergic Receptor Antagonist

The general purpose of an alpha-1-blocker like Doxazosin is fundamentally linked to its ability to cause smooth muscle relaxation. The underlying physiological action involves postsynaptic alpha-1 adrenoceptor blockade, which interrupts signals that cause the tightening of blood vessels. This effect leads to vasodilation, which systematically decreases peripheral vascular resistance. Consequently, this mechanism serves to manage elevated pressure within the circulatory system and relieve tension in smooth muscle structures of non-vascular organs, positioning it as both a cardiovascular agent and a urological agent. This type of medicine helps manage elevated pressure by relaxing the walls of blood vessels.

What side effects are possible with Dilur?

Possible Side Effects and Safety Information

The official safety profile of Dilur (Doxazosin) is structured by governmental regulatory agencies to define the documented risks and specific considerations associated with its use. Side effects are classified by frequency based on clinical data and grouped by the System Organ Class (SOC) they affect, including cardiovascular, nervous system, and gastrointestinal disorders.

Commonly Documented Adverse Reactions

Adverse reactions classified as Very Common (ge 1/10) include Dizziness, Fatigue, and Malaise. Effects listed as Common (ge 1/100 to < 1/10) include Postural Hypotension (a drop in blood pressure upon standing), Headache, Somnolence (drowsiness), Palpitations, and Peripheral Oedema (swelling).

Safety Patterns and Serious Reactions

The risk of Postural Hypotension is explicitly noted to occur most frequently shortly after the initial dose or following a dose increase. Serious but less common reactions documented in the regulatory profile include Syncope (loss of consciousness), Myocardial Infarction, and Angina Pectoris. Very rare but clinically significant events include Priapism (prolonged erection) and severe Hepatobiliary Disorders such as Hepatitis and Jaundice.

Safety Considerations for Specific Populations

Dilur is not recommended for use in individuals with severe hepatic impairment due to lack of established clinical data. Safety and efficacy have not been established in the pediatric population. The official labeling also documents the risk of Intraoperative Floppy Iris Syndrome (IFIS), a potential complication during cataract surgery, in patients taking or previously treated with Doxazosin. Use is contraindicated in individuals with certain pre-existing conditions, including overflow bladder, anuria, and progressive renal insufficiency.

Overdose and Emergency Response

Overdose and When to Seek Help

This section details the officially documented manifestations of Dilur (Doxazosin) overdose and the required emergency actions, as described in government regulatory documents.


Documented Overdose Manifestations

The most significant and officially documented manifestation of a Doxazosin overdose is Hypotension (a substantial drop in blood pressure), which is an exaggerated effect of the medicine's primary action. Other documented signs can include dizziness, lightheadedness, and drowsiness.

Severe manifestations recorded in regulatory-cited data may include syncope (fainting) and the potential for seizure.

Officially Required Emergency Actions

Urgent Medical Help: If an overdose is suspected, it is required to seek emergency medical attention immediately (e.g., calling emergency services or Poison Control).

Management Principles: The management is primarily supportive, as official labeling confirms no specific antidote is available for Doxazosin overdose. The most important action is support of the cardiovascular system to stabilize blood pressure and heart rate.

  • Initial Action: The patient should be placed in a supine, head down position (Trendelenburg).
  • Stabilization: Treatment for shock, if positioning is insufficient, involves administering volume expanders (intravenous fluids), followed by vasopressors if blood pressure remains unstable.
  • Monitoring: Closely monitor vital signs throughout the management process.

Procedural Note: Due to the drug's high protein binding, regulatory sources state that dialysis is not expected to be of benefit in treating an overdose.

Therapeutic Uses of Dilur

What Dilur Treats: Main Uses and Benefits

Dilur (Doxazosin) is generally considered relevant for two core therapeutic areas: elevated systemic pressure (hypertension) and the symptoms of Benign Prostatic Hyperplasia (BPH). The medication is commonly used to help manage both conditions.

Symptom Domains and Therapeutic Support

Dilur is considered relevant in settings where supportive symptom management is appropriate for conditions characterized by periods of heightened symptoms and functional strain. It is applied across therapeutic domains involving chronic hypertension and Lower Urinary Tract Symptoms (LUTS).

For elevated systemic pressure, it assists with managing chronic high pressure, which is a condition associated with systemic imbalance. For BPH, it is used to help manage symptom clusters that interfere with daily comfort, such as difficulty initiating flow, frequent urgency, and nocturia. The medication is often applied in scenarios where additional management of discomfort is required, providing supportive relief that may assist with maintaining functional stability.

“This medication is commonly used when symptoms cluster into patterns requiring supportive management, assisting with maintaining functional stability.”

The use of Dilur is relevant for addressing both elevated pressure and BPH symptoms in the same patient.

Quick Fact: Urological Symptom Support
Urological Symptom Support: Assists in easing the physical discomfort and functional strain associated with a weak urinary stream and the feeling of incomplete bladder emptying.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Dilur?

This section outlines the official population eligibility and non-eligibility rules for Dilur (Doxazosin) as stated in government regulatory documents.

Contraindications and Non-Eligibility

Dilur is strictly contraindicated (must not be used) in patients with a known hypersensitivity to doxazosin, other quinazoline derivatives (e.g., prazosin, terazosin), or any components of the tablet. Use is also contraindicated in patients with a history of symptomatic orthostatic hypotension (low blood pressure upon standing). For the treatment of Benign Prostatic Hyperplasia (BPH), it is also contraindicated in patients with existing hypotension (low blood pressure) or those with overflow bladder or anuria (absence of urine output).

Population-Specific Restrictions

Population Group Eligibility Status (Regulatory)
Pediatric (Under 18) Not recommended; safety and efficacy have not been established.
Severe Hepatic Impairment Not recommended due to a lack of clinical experience.
Pregnancy/Lactation Use is contraindicated during breastfeeding and is only recommended during pregnancy if clearly needed.
BPH Pre-Treatment Carcinoma of the prostate must be ruled out before commencing therapy.
Older Adults (Geriatric) Allowed, but requires special care due to increased risk of orthostatic hypotension.

What should I know about interactions with other medicines?

Dilur Interactions with other medicines and products

Dilur (Doxazosin) has an official interaction profile classified by regulatory authorities based on metabolic and pharmacodynamic effects. The drug is identified as a substrate of the CYP3A4 enzyme. Co-administration with a Strong CYP3A4 Inhibitor (e.g., ritonavir, ketoconazole) may cause increased systemic exposure to Doxazosin, a documented pharmacokinetic interaction. This finding results in official statements urging caution during co-administration. Doxazosin is documented as having no effect on the protein binding of standard agents such as digoxin, phenytoin, or warfarin.


Pharmacodynamic and Timing Constraints

Pharmacodynamic reinforcement is a core classification, resulting in additive effects with other blood pressure-lowering agents. Concomitant use with Phosphodiesterase Type-5 (PDE-5) Inhibitors (e.g., sildenafil) results in additive blood pressure lowering effects. Regulatory documents define a procedural constraint for this interaction: PDE-5 inhibitor treatment must be initiated only when the patient is demonstrated to be stable on Doxazosin therapy.

Regarding substances and timing, alcohol consumption is officially noted as possibly increasing the blood pressure-lowering effect. The extended-release formulation has an administrative timing rule requiring consumption with breakfast. Finally, a population-specific note advises caution for patients with impaired hepatic function. Because the drug is wholly metabolized by the liver, this population carries a documented risk of reduced clearance and drug or metabolite accumulation.

Mechanism of Action

Dilur (Doxazosin) works by a mechanism of competitive antagonism that selectively targets the Alpha-1 Adrenergic Receptors (alpha1-AR) found on the surface of smooth muscle cells. This action prevents the natural signaling molecule, Norepinephrine, from binding and activating these receptors. The subsequent disruption of the Gq protein signaling cascade leads to a decrease in the concentration of intracellular calcium ions ( Ca^2+), which is essential for muscle contraction.

Blocking the Sympathetic Control of Vascular Tone

By blocking the alpha1B receptor subtype in the walls of arterioles, Doxazosin dampens the signals from the Sympathetic Nervous System that cause blood vessel constriction. This results in vasodilation (vessel widening), which is the primary molecular driver for lowering the Systemic Vascular Resistance (SVR), a fundamental change in vascular resistance dynamics.

Modulating Urogenital Smooth Muscle Tension

The mechanism relaxes the smooth muscle surrounding the base of the bladder, the bladder neck, and the prostate capsule by inhibiting sympathetic signals via the alpha1A receptor subtype. This targeted relaxation results in a reduction of smooth muscle tone and a decrease in mechanical resistance within the lower urinary tract structures.

Mechanism Constraint: Interference with Compensatory Reflexes

The drug's core mechanism inherently limits the body's rapid ability to execute the baroreceptor reflex, which requires alpha1-AR-mediated vasoconstriction upon standing. This physiological constraint highlights a transient limitation where the pharmacological action suppresses the sympathetic signal required for rapid, compensatory vasoconstriction.

Dosage and Administration Information

How to Use Dilur: Dosing and Administration

Dilur (Doxazosin) must be administered according to standard procedures, focusing on the correct form, timing, and dose titration.

Approved Forms and Route

Doxazosin is available as Immediate-Release (IR) tablets and Extended-Release (ER) tablets. The only approved method of intake for both forms is the oral route (by mouth).

Dosage Form Strengths Available Key Administration Rule
Immediate-Release (IR) 1 mg, 2 mg, 4 mg, 8 mg May be taken with or without food.
Extended-Release (ER) 4 mg, 8 mg Must be taken with breakfast.

Standard Dosing Regimens and Frequency

Dilur is administered once daily (qDay). Dosing begins with a low starting dose and is gradually increased through a process called titration.

Condition Starting Dose Maximum Daily Dose
Hypertension (IR) 1 mg 16 mg
BPH (IR and ER) 1 mg (IR) or 4 mg (ER) 8 mg

Titration involves increasing the dose at intervals of 1 to 4 weeks, as specified in standard clinical documentation.

Special Administration Instructions

All tablets must be swallowed whole with liquid. It is a mandatory instruction that extended-release tablets must not be chewed, crushed, divided, or cut, as this would disrupt the controlled-release mechanism.

If Doxazosin therapy is discontinued for several days, it is required to re-start the medication at the initial dose and re-titrate the dosage gradually. No dose adjustment is typically needed for patients with renal impairment.

Recent Clinical Evidence

Research evidence / Overview of studies for Dilur


Evidence for Use in Symptomatic Benign Prostatic Hyperplasia (BPH)

Research exploring the use of Dilur for conditions involving periods of heightened symptoms related to Benign Prostatic Hyperplasia (BPH) primarily involves well-structured Randomized Controlled Trials (RCTs). Researchers used these studies to monitor patient outcomes related to physical discomfort and functional imbalance over defined time intervals, typically around 9 to 16 weeks.

The trials monitored measurements, such as the International Prostate Symptom Score (IPSS), which is a patient-reported outcome describing perceived discomfort, to observe how symptoms were tracked in the studied populations. Findings describe patterns observed in the studies where differences in these measured symptoms were recorded compared to the start of the trial.


Evidence for Use in Elevated Systemic Pressure (Hypertension)

Dilur was evaluated in research for managing high blood pressure, focusing on its use both as a single treatment (monotherapy) and as an add-on therapy. The studies monitored outcomes related to systemic or functional imbalance by measuring patterns related to systolic and diastolic blood pressure (SBP/DBP) in adults with essential hypertension. Researchers also monitored other physiological markers, such as patterns in certain serum lipid profiles.

In these research scenarios, findings indicate that studies consistently reported patterns related to measurements of SBP and DBP in the observed populations, where differences from baseline were observed. Comparative evidence, however, is lacking for some critical long-term cardiovascular outcomes when Dilur is used alone, due to the early discontinuation of the monotherapy arm in a major comparative trial.


What is Still Uncertain About Dilur's Research

A primary gap in the research landscape is the limited information for long-term outcomes regarding cardiovascular events when Dilur is used as the sole treatment for hypertension. Furthermore, long-term data for both BPH and hypertension often comes from observational settings, where the data quality differs from the initial, short-term, double-blind RCTs. Data for pediatric populations (children and adolescents) remains insufficient.

Frequently Asked Questions (FAQ)

Common questions about Dilur (FAQ)


Q: Is it normal to feel a minor side effect when starting Dilur?

Official information indicates that the risk of certain side effects, particularly low blood pressure upon standing (postural hypotension), dizziness, and fainting, is greatest shortly after the very first dose or when the dosage is increased. This known pattern is documented in the official safety profile.


Q: Can Dilur affect my driving ability?

Regulatory documents caution that Dilur may cause effects like dizziness and somnolence (drowsiness). Due to these central nervous system effects, official labeling describes the need for caution when driving or operating complex machinery, particularly when starting treatment or increasing the dose.


Q: Are there any food or drinks I should avoid while on Dilur?

Official product information notes that alcohol consumption can potentially enhance the blood pressure-lowering effect of Dilur. This increase in effect raises the risk of experiencing dizziness or fainting, which are associated side effects.


Q: What is the half-life of Dilur?

According to official pharmacokinetic data, the active ingredient in Dilur has a mean plasma elimination half-life of approximately 22 hours. This measured rate of clearance helps inform the once-daily administration schedule.


Q: How long does Dilur stay in your system after stopping it?

The drug’s active component has a half-life of about 22 hours, meaning it takes that long for half the medicine to be cleared from the bloodstream. While it generally takes several days for a drug to be fully eliminated from the system, the precise time may be subject to individual patient differences.


Q: What happens if I forget to take a dose of Dilur?

Official patient information advises that if you miss a dose, you should take it as soon as you recall it. However, if it is nearly time for the next dose, official label instructions indicate that the missed dose should be skipped. Regulatory information states that double or extra doses should not be taken.


Q: Can I stop taking Dilur suddenly?

Regulatory documentation indicates that if treatment is interrupted for a period of several days or more, the procedure involves re-starting at the initial low dose and gradually re-titrating the dosage. This emphasizes that treatment should not be stopped or started without consulting a healthcare professional.


Q: Is it better to take Dilur in the morning or at night?

To help manage the risk of low blood pressure (hypotension) and dizziness when beginning treatment, official information notes that the initial dose is sometimes taken at bedtime. Subsequent dosing timing will be determined based on the specific formulation and individual response.


Q: Does Dilur interact with common pain relievers like ibuprofen?

Official interaction references note that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which include pain relievers such as ibuprofen, may potentially reduce the blood pressure-lowering effect of Dilur. This is a documented pharmacodynamic interaction.


Q: Will Dilur interact with birth control pills?

According to available information, Dilur is not known to directly interfere with the effectiveness of hormonal contraception, such as birth control pills. However, some combined hormonal contraceptives may not be recommended for individuals managing high blood pressure, and a healthcare provider can offer clarity regarding the use of these combined medications.


Q: Is Dilur associated with any mental health changes or mood swings?

The documented safety profile includes adverse reactions that affect the nervous system, such as anxiety and insomnia (difficulty sleeping). This information is based on data collected during clinical trials and post-marketing surveillance.


Q: Is Dilur used for conditions other than its primary indication?

The drug is officially approved for managing high blood pressure and relieving BPH symptoms. Regulatory information does not cover other uses, but its properties have led to it being examined for purposes like treating PTSD-related nightmares in some clinical settings. Any use outside of its approved indications is considered off-label.


Q: What kind of monitoring is needed while using Dilur?

Official guidance specifies that monitoring should focus on blood pressure and any symptoms of low blood pressure. For BPH treatment, official guidance indicates that prostate carcinoma (prostate cancer) should be ruled out before beginning therapy.


Q: Do different strengths of Dilur have different side effects?

Official documents indicate that the general side effect profile of the medicine remains consistent across different strengths. However, the risk of experiencing effects like low blood pressure upon standing is explicitly noted to increase shortly after any adjustment or increase in dosage.


Q: Is it possible to overdose on Dilur?

As with all prescription medicines, an overdose is possible. Regulatory patient information notes that an overdose may result in symptoms such as extreme dizziness, lightheadedness, drowsiness, and fainting. If these symptoms are observed, seeking immediate emergency medical assistance is indicated in the official documentation.


Q: Can Dilur be used by people with diabetes?

Clinical data summarized in official sources indicate that Dilur is considered suitable for use in patients who also have diabetes mellitus or insulin resistance. Studies have generally shown that it does not appear to cause adverse metabolic effects in this population.


Q: Does Dilur affect or change the results of blood tests?

Studies have indicated that, beyond its intended uses, the medicine may produce modest changes in certain blood test results. Specifically, there is evidence that it can lead to small reductions in plasma concentrations of total cholesterol, LDL-cholesterol, and triglycerides.


Q: Does Dilur work differently in men versus women?

While one of its primary uses is male-specific (BPH), the general mechanism of action for blood pressure is systemic. Regulatory documents note that studies in older adults of either sex have not demonstrated major differences in how the body processes the drug (pharmacokinetics).


Q: Is Dilur a controlled substance or addictive?

Dilur is classified as a prescription-only medicine (an alpha1-adrenergic blocker) and is not designated as a controlled substance in official lists. Additionally, research indicates that the development of tolerance or dependence has not been observed during long-term use.


Q: Is Dilur expensive, and is there a generic version available?

The active ingredient in Dilur, Doxazosin, is officially available as a generic medication. The availability of a generic version may influence the cost of the medicine.


Q: What does the research say about the long-term safety of Dilur?

Available research evidence highlights a gap concerning the long-term safety profile when the drug is used as the sole treatment (monotherapy) for high blood pressure. Regulatory reviews explicitly note that there is limited information regarding long-term cardiovascular outcomes in this specific context.

How should Dilur be stored and disposed of?

Storage and Disposal Requirements for Dilur (Doxazosin)

Dilur tablets must be stored at Controlled Room Temperature (CRT), which is defined as 20 C to 25 C (68 F to 77 F). The product must be protected from both freezing and excessive heat. To maintain stability, the medicine must be stored in its original container and kept tightly closed to protect it from light and moisture.

It is a mandatory safety instruction to keep Dilur out of the reach of children.

Unused or expired Dilur must be disposed of according to local regulatory procedures. The safest method of disposal is typically a drug take-back program. Doxazosin is not on the official list of medications recommended for flushing; therefore, it should not be disposed of by pouring it down a sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dilur found in:

A-Z Index: